Samrat Pharmachem logo

Samrat Pharmachem

SAMRATPHARMACHEMLTD NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹71.35 Cr
Volatility
Moderate
P/E Ratio
-32.4
EBITDA
₹-1.30 Cr
Return on Equity
-4.86%
Debt to Equity
0.16
Book Value
₹220.67
EPS
₹7
52W High
₹333
52W Low
₹190

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Stock is trading at 1.03 times its book value

Weaknesses

3
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 10.1% over past five years.
  • Company has a low return on equity of 2.15% over last 3 years.

Growth Rate

Revenue Growth
1.32% higher than 3Y
Net Income Growth
-146% higher than 3Y
Cash Flow Change
188% higher than 3Y
ROE
-149% lower than 3Y
ROCE
-120% higher than 3Y
EBITDA Margin (Avg.)
-112% higher than 3Y

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
57.48
79.74
61.67
82.68
80.82
70.17
63.66
71.2
75.65
78.87
63.43
71.77
79.76
Expenses
56.71
79.51
61.56
81.32
78.24
66.8
59.48
71.07
75.52
79.23
64.08
73.01
78.87
Operating Profit
0.77
0.23
0.11
1.36
2.58
3.37
4.18
0.13
0.13
-0.36
-0.65
-1.24
0.89
OPM %
1.34%
0.29%
0.18%
1.64%
3.19%
4.8%
6.57%
0.18%
0.17%
-0.46%
-1.02%
-1.73%
1.12%
Other Income
0.36
0.3
0.42
0.3
0.59
0.49
0
-0.11
0.69
0.05
0.4
-0.31
0.99
Interest
0.22
0.13
0.23
0.11
0.19
0.17
0.1
0.22
0.44
0.26
0.13
0.14
0.11
Depreciation
0.16
0.16
0.16
0.16
0.16
0.17
0.17
0.16
0.17
0.18
0.19
0.19
0.19
PBT
0.75
0.24
0.14
1.39
2.82
3.52
3.91
-0.36
0.21
-0.75
-0.57
-1.88
1.58
Tax %
18.67%
175%
-142.86%
0%
26.6%
24.43%
28.9%
11.11%
209.52%
-21.33%
-19.3%
8.51%
44.94%
Net Profit
0.61
-0.19
0.34
1.4
2.07
2.66
2.78
-0.4
-0.23
-0.59
-0.46
-2.04
0.88
EPS in Rs
1.97
-0.61
1.1
4.53
6.7
8.61
9
-1.29
-0.74
-1.91
-1.49
-6.6
2.85
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
47
63
73
93
111
137
179
222
311
282
286
290
294
Expenses
46
62
69
87
108
131
170
197
287
279
276
292
295
Operating Profit
1
1
4
6
3
7
9
24
24
2
10
-2
-1
OPM %
2.5%
1.9%
5%
6%
2.9%
4.8%
4.8%
11%
8%
0.9%
3.6%
-0.7%
-0.5%
Other Income
0
0
0
0
0
1
0
1
0
1
1
1
1
Interest
1
1
1
1
1
1
1
1
1
1
1
1
1
Depreciation
0
0
0
0
0
0
0
1
1
1
1
1
1
PBT
0
0
3
5
2
6
7
24
23
3
10
-3
-2
Tax %
35%
33%
37%
35%
29%
27%
27%
27%
26%
14%
28%
11%
—
Net Profit
0
0
2
3
2
4
5
17
17
2
7
-3
-2
EPS in Rs
1.04
0.97
5.66
10.42
4.98
13.72
17.25
55.6
53.82
6.99
23.01
-10.71
-7.15
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
2%
2%
14%
4%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
3
3
3
3
3
3
3
3
3
3
3
3
Reserves
10
11
12
15
17
21
27
44
60
62
69
65
Borrowings
3
6
7
9
7
9
9
8
19
8
10
11
Other Liabilities
10
17
14
13
14
25
19
30
35
48
40
46
Total Liabilities
26
36
36
41
40
58
57
85
117
122
122
124
Fixed Assets
7
7
7
7
7
7
9
10
11
11
10
12
CWIP
0
0
0
0
0
1
0
0
0
0
0
1
Investments
0
2
0
0
0
0
0
0
2
3
4
4
Other Assets
19
27
29
34
33
50
48
75
104
108
107
108
Total Assets
26
36
36
41
40
58
57
85
117
122
122
124
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-1
0
-3
0
2
-1
5
17
-9
9
-10
9
Investing
0
-2
1
-2
2
-2
-3
-1
-3
0
0
-3
Financing
0
2
1
2
-4
2
-2
-2
10
-11
0
0
Net Cash Flow
0
0
-1
-1
1
-1
0
14
-3
-2
-10
6
Free Cash Flow
-1
-1
-4
0
2
-3
3
16
-11
9
-11
6
CFO/OP
-29
-25
-73
17
126
-7
81
78
0
503
-84
-493
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
74
93
59
86
69
74
67
72
61
90
72
64
Inventory Days
38
37
41
31
28
55
25
24
43
28
52
56
Days Payable
76
104
43
46
45
67
39
45
42
65
53
55
Cash Conversion Cycle
36
26
58
70
52
61
53
51
62
53
71
65
Working Capital Days
19
14
34
32
37
39
36
32
40
47
68
52
ROCE %
7%
5%
16%
23%
12%
22%
24%
52%
35%
3%
13%
-3%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Samrat Pharmachem insights

65 extracted metrics + investor summaries across FY11–FY26.

Log in — free

Shareholding Pattern

FIIs3.24%Promot.49.09%Others6.16%Public41.51%As ofJun 2026

Documents

Frequently Asked Questions about Samrat Pharmachem

What does Samrat Pharmachem Ltd do?
Incorporated in 1992, Samrat Pharmachem Ltd does manufacturing and selling of chemicals[1]
Where is Samrat Pharmachem Ltd (530125) listed?
Samrat Pharmachem Ltd trades as SAMRATPHARMACHEMLTD on the NSE and under code SAMRATPH on the BSE.
Which sector does Samrat Pharmachem Ltd belong to?
Samrat Pharmachem Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Samrat Pharmachem Ltd?
Samrat Pharmachem Ltd has a market capitalisation of ₹71.35 Cr, which places it in the Small Cap band.
What is the PE ratio of Samrat Pharmachem Ltd?
Samrat Pharmachem Ltd trades at a PE ratio of -32.40, on earnings per share of ₹7, against a book value of ₹220.67 per share.
What is the 52-week high and low of Samrat Pharmachem Ltd?
Over the last 52 weeks Samrat Pharmachem Ltd has traded between ₹190 and ₹333.
Does Samrat Pharmachem Ltd pay dividends?
Samrat Pharmachem Ltd has a dividend yield of 0.43%.
What is the Return on Equity (ROE) of Samrat Pharmachem Ltd?
Samrat Pharmachem Ltd reported a return on equity of -4.86%. Its debt-to-equity ratio is 0.16.

Company Information

Incorporated in 1992, Samrat Pharmachem Ltd does manufacturing and selling of chemicals[1]

Website samratpharmachem.com
Face Value ₹ 10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/530125.md for Samrat Pharmachem Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List